A Weak Prognosis for Vytorin and Zetia
In what may go down as a seminal lesson in the dangers of over-aggressive drug-industry marketing, share prices of Schering-Plough (SGP) and Merck (MRK) plunged on Mar. 31 after their top-selling cholesterol drugs got hammered at a scientific meeting. Schering shares were down 26% at the close of trading on Mar. 31, to 14.41, and Merck was down 14.7%, to 37.95—representing a combined loss of $22 billion in shareholder value from the previous Friday.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Smartphones Are Killing Americans, But Nobody’s Counting
- Why a Pub in the Middle of Nowhere Was Named the World’s Best Restaurant
- Gulf Coast Oil Spill May Be Largest Since 2010 BP Disaster
- Marc Faber Asked to Leave Sprott Board After Racist Report
- Airbus Snaps Up Bombardier Jet in New Challenge to Boeing